Baudax Bio to Report First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 5, 2021
29 April 2021 - 9:00PM
Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused
on developing and commercializing innovative products for acute
care settings, today announced that it will report first quarter
2021 financial results on Wednesday, May 5, 2021. Baudax Bio’s
management team will host a conference call and webcast at 8:00
a.m. ET on Wednesday, May 5, 2021 to discuss the financial results
and recent operational highlights.
To access the conference call please dial (866)
220-5595 (local) or (615) 622-8062 (international) at least 10
minutes prior to the start time and refer to conference ID 5444429.
A live audio webcast of the call will be available under “Events”
in the Investor section of the Company’s website,
https://www.baudaxbio.com/news-and-investors/events. An archived
webcast will be available on the Company’s website approximately
two hours after the event and will be available for 30 days.
About Baudax Bio
Baudax Bio is a pharmaceutical company focused
on developing and commercializing innovative products for acute
care settings. The launch of Baudax Bio’s first commercial product
ANJESO® began in mid-2020. ANJESO is the first and only 24-hour,
intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory
(NSAID) for the management of moderate to severe pain, which can be
administered alone or in combination with other non-NSAID
analgesics. It has successfully completed three Phase III clinical
trials, including two pivotal efficacy trials, a large double-blind
Phase III safety trial and a Phase IIIB program evaluating ANJESO
and its health economic impact in specific surgical settings. In
addition to ANJESO, Baudax Bio has a pipeline of other innovative
pharmaceutical assets including two novel neuromuscular blocking
agents (NMBAs) and a proprietary chemical reversal agent specific
to these NMBAs which is currently in preclinical studies. For more
information, please visit www.baudaxbio.com.
Cautionary Statement Regarding Forward Looking
Statements
This press release contains forward-looking
statements that involve risks and uncertainties. Such
forward-looking statements reflect Baudax Bio’s expectations about
its future performance and opportunities that involve substantial
risks and uncertainties. When used herein, the words “anticipate,”
“believe,” “estimate,” “may,” “upcoming,” “plan,” “target,” “goal,”
“intend,” and “expect,” and similar expressions, as they relate to
Baudax Bio or its management, are intended to identify such
forward-looking statements. These forward-looking statements are
based on information available to Baudax Bio as of the date of
publication on this internet site and are subject to a number of
risks, uncertainties, and other factors that could cause Baudax
Bio’s performance to differ materially from those expressed in, or
implied by, these forward-looking statements. These forward-looking
statements are subject to risks and uncertainties including, among
other things, the completion of the registered direct offering and
the intended use of proceeds from the registered direct offering,
the ongoing economic and social consequences of the COVID-19
pandemic, including any adverse impact on the commercial launch of
ANJESO® or disruption in supply chain, Baudax Bio’s ability to
maintain regulatory approval for ANJESO, Baudax Bio’s ability to
successfully commercialize ANJESO; the acceptance of ANJESO by the
medical community, including physicians, patients, health care
providers and hospital formularies; Baudax Bio’s ability and that
of Baudax Bio’s third party manufacturers to successfully scale-up
our commercial manufacturing process for ANJESO, Baudax Bio’s
ability to produce commercial supply in quantities and quality
sufficient to satisfy market demand for ANJESO, Baudax Bio’s
ability to raise future financing for continued product
development, payment of milestones and ANJESO commercialization,
Baudax Bio’s ability to pay its debt and satisfy conditions
necessary to access future tranches of debt, Baudax Bio’s ability
to comply with the financial and other covenants under its credit
facility, Baudax Bio’s ability to manage costs and execute on our
operational and budget plans, the accuracy of Baudax Bio’s
estimates of the potential market for ANJESO, Baudax Bio’s ability
to achieve its financial goals; and Baudax Bio’s ability to obtain,
maintain and successfully enforce adequate patent and other
intellectual property protection. These forward-looking statements
should be considered together with the risks and uncertainties that
may affect Baudax Bio’s business and future results included in
Baudax Bio’s filings with the Securities and Exchange Commission at
www.sec.gov. These forward-looking statements are based on
information currently available to Baudax Bio, and Baudax Bio
assumes no obligation to update any forward-looking statements
except as required by applicable law.
CONTACT:
Investor Relations Contact:Argot PartnersSam Martin / Claudia
Styslinger(212) 600-1902baudaxbio@argotpartners.com
Media Contact:Argot PartnersDavid Rosen(212)
600-1902david.rosen@argotpartners.com
Baudax Bio (NASDAQ:BXRX)
Historical Stock Chart
From Apr 2024 to May 2024
Baudax Bio (NASDAQ:BXRX)
Historical Stock Chart
From May 2023 to May 2024